Charité - Universitätsmedizin Berlin

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update (2017) Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, Castillejo G, et al. Journal article Toward evidence-based diagnosis of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform (2017) Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Bocker D, Jakob A, et al. Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution OLAPARIB IN GERMAN ROUTINE CLINICAL PRACTICE - INTERIM RESULTS OF THE NON-INTERVENTIONAL STUDY C-PATROL (2017) Marme F, Sehouli J, Welslau M, Schinkoethe T, El-Balat A, Fasching P, Glowik R, Hilpert F Conference contribution Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017) (2017) Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, et al. Journal article Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) Hahnen E, Lederer B, Hauke J, Loibl S, Kroeber S, Schneeweiss A, Denkert C, et al. Journal article Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity (2017) Fasching P, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, et al. Journal article A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) (2017) Sehouli J, Tome O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, et al. Journal article